Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Perspective Therapeutics (CATX) Net Margin (2016 - 2025)

Perspective Therapeutics (CATX) has disclosed Net Margin for 16 consecutive years, with 300.58% as the latest value for Q2 2025.

  • Quarterly Net Margin rose 39800.0% to 300.58% in Q2 2025 from the year-ago period, while the trailing twelve-month figure was 101.18% through Dec 2025, up 16868.0% year-over-year, with the annual reading at 101.18% for FY2025, 16868.0% up from the prior year.
  • Net Margin hit 300.58% in Q2 2025 for Perspective Therapeutics, up from 97.42% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 300.58% in Q2 2025 to a low of 236.92% in Q3 2022.
  • Historically, Net Margin has averaged 41.33% across 5 years, with a median of 64.01% in 2023.
  • Biggest five-year swings in Net Margin: plummeted -14944bps in 2022 and later soared 39800bps in 2025.
  • Year by year, Net Margin stood at 56.96% in 2021, then crashed by -316bps to 236.92% in 2022, then soared by 157bps to 136.22% in 2023, then tumbled by -172bps to 97.42% in 2024, then soared by 409bps to 300.58% in 2025.
  • Business Quant data shows Net Margin for CATX at 300.58% in Q2 2025, 97.42% in Q2 2024, and 155.07% in Q1 2024.